Biome Australia Limited (BIO.AX)
AUD 0.47
(-5.05%)
AUD 0.47
(-5.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -1.57 Million AUD | 48.38% |
| 2023 | -3.05 Million AUD | 30.88% |
| 2022 | -4.64 Million AUD | 18.34% |
| 2021 | -5.38 Million AUD | -109.32% |
| 2020 | -3.24 Million AUD | -36.48% |
| 2019 | -3274.00 AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -1.46 Million AUD | -92.59% |
| 2024 FY | - AUD | 45.32% |
| 2024 Q4 | -210.96 Thousand AUD | 0.0% |
| 2024 Q1 | -854.66 Thousand AUD | 40.95% |
| 2023 Q2 | -1.47 Million AUD | -76.67% |
| 2023 FY | - AUD | 30.88% |
| 2023 Q4 | -1.58 Million AUD | -102.57% |
| 2023 Q3 | -781.77 Thousand AUD | 46.96% |
| 2023 Q1 | -834.24 Thousand AUD | 52.35% |
| 2022 Q1 | -1.34 Million AUD | 41.51% |
| 2022 FY | - AUD | 18.34% |
| 2022 Q4 | -1.75 Million AUD | -70.91% |
| 2022 Q3 | -1.02 Million AUD | 57.18% |
| 2022 Q2 | -2.39 Million AUD | -78.0% |
| 2021 Q3 | -1.1 Million AUD | 64.48% |
| 2021 Q4 | -2.29 Million AUD | -107.5% |
| 2021 FY | - AUD | -109.32% |
| 2021 Q1 | -1.7 Million AUD | 0.0% |
| 2021 Q2 | -3.11 Million AUD | -82.69% |
| 2020 FY | - AUD | -36.48% |
| 2019 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | 70.237% |
| Acrux Limited | -7.93 Million AUD | 80.1% |
| Actinogen Medical Limited | -12.92 Million AUD | 87.786% |
| AnteoTech Limited | -11.57 Million AUD | 86.36% |
| Argenica Therapeutics Limited | -1.89 Million AUD | 16.829% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 82.133% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -8.347% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 91.936% |
| Amplia Therapeutics Limited | -4.55 Million AUD | 65.386% |
| Avecho Biotechnology Limited | -3.24 Million AUD | 51.326% |
| Bio-Gene Technology Limited | -2.97 Million AUD | 46.949% |
| Biotron Limited | -5.04 Million AUD | 68.686% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 88.661% |
| BTC Health Limited | 1.05 Million AUD | 249.557% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 86.033% |
| CSL Limited | 4.73 Billion AUD | 100.033% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 96.465% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 103.043% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 84.139% |
| Dimerix Limited | -24.95 Million AUD | 93.677% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 115.211% |
| Hexima Limited | -995.54 Thousand AUD | -58.532% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | 43.996% |
| Immuron Limited | -6.19 Million AUD | 74.513% |
| Immutep Limited | -42.87 Million AUD | 96.319% |
| Imugene Limited | -147.97 Million AUD | 98.933% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -119.067% |
| Memphasys Limited | -3.3 Million AUD | 52.286% |
| Nanollose Limited | -1.14 Million AUD | -37.49% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 100.792% |
| Noxopharm Limited | -5.94 Million AUD | 73.455% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | 12.138% |
| Nyrada Inc. | -4.59 Million AUD | 65.662% |
| Orthocell Limited | -11.68 Million AUD | 86.489% |
| PharmAust Limited | -9.45 Million AUD | 83.302% |
| Patrys Limited | -3.49 Million AUD | 54.806% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 97.555% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 79.99% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 78.036% |
| PYC Therapeutics Limited | -38.11 Million AUD | 95.86% |
| Race Oncology Limited | -14.2 Million AUD | 88.888% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 96.522% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 92.609% |
| Starpharma Holdings Limited | -12.57 Million AUD | 87.451% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 106.872% |
| Tissue Repair Ltd | -5.77 Million AUD | 72.671% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 95.669% |